Cardiol Therapeutics shares surge 10.07% intraday after announcing $13.5M bought deal financing for heart disease research and trials.

Cardiol Therapeutics surged 10.07% intraday following the announcement of a $13.5 million bought deal private placement with Canaccord Genuity Corp. The financing involves issuing 10.38 million units at $1.30 per unit, with each unit including one common share and one-half warrant exercisable at $1.75. The proceeds will advance Cardiol’s research and clinical development programs, including trials for its lead drug candidate, CardiolRx™, targeting heart diseases. The offering, expected to close on January 23, 2026, also includes an underwriter option to purchase up to 10% additional units. The capital raise signals investor confidence in the company’s pipeline and strategic focus on anti-inflammatory therapies, directly driving the intraday price rally.